Outcomes of Intracoronary AAV1/SERCA2a Gene Therapy in Patients With Heart Failure With Preserved Ejection Fraction: 12-Month Results From the MUSIC-HFpEF Phase 1/2a Trial

31 August 2026 (11:15 - 11:30)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Doctor Marat Fudim

Duke Clinical Research Institute, Durham (United States of America)

3 More presentations in this session

Presentation thumbnail

CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

Doctor A. Owens (Philadelphia, US)

Presentation thumbnail

The autoregulated bioprosthetic total artificial heart in advanced biventricular failure: 180-day outcomes from the EFICAS study

Professor A. Vincentelli (Lille, FR)

Presentation thumbnail

Intravenous Dexrazoxane for Hemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial (SHIELD-MI)

Doctor K. Vora (Indianapolis, US)

Access the full session

Session thumbnail

Transforming the heart: novel therapies for myocardial disease and heart failure

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET

You may be interested in

Congress Presentation

Gene therapy for heart failure with preserved ejection fraction

18 May 2025

Congress Session

Transforming heart failure with next-generation therapies and mechanisms

31 August 2026

Congress Presentation

GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction

29 August 2026

Congress Presentation

Advances in the treatment of HFpEF

20 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources